Boston, USA - Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has signed an Memorandum of Understanding (MOU) with New Zealand Clinical Research (NZCR).

Novotech’s Senior Therapeutic Strategy Manager, Dr. Shawnna Barrett, and Senior Business Development Manager, Lainie Mulvanny, will announce the MOU at the 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston, MA, on May 23-24, 2024.

NZCR, which has 4 sites across New Zealand, is a leading early phase research center with a strong track-record conducting psychedelics studies.

Novotech has previously collaborated with NZCR on multiple psychedelic studies. This partnership further signals Novotech’s commitment to pioneering research in the field of psychedelic medicines.

For decades, Novotech has been establishing relationships with specialized clinical research sites worldwide, ensuring clients receive priority access to some of the most experienced sites and clinical teams.

The global market for psychedelic drugs, was estimated at US$5.50 Billion in 2023, and is projected to grow 13% from 2024 to 2030, with revenues anticipated to reach close to US$ 12.94 Billion.

Psychedelic drugs come in three main categories: 
dissociative pharmaceuticals like phencyclidine (PCP)
empathogens like 3,4-Methyl​enedioxy​methamphetamine (MDMA; ecstacy)
serotonergic drugs such as lysergic acid diethylamide (LSD)

The leading drugs being investigated in trials are psilocybin, LSD, ketamine hydrochloride, and mebufotenin.

A Novotech review of current research applications reveals that CNS disorders are the leading therapeutic area in global psychedelic drug trials, with primary indications including depression, anxiety disorders, pain, and substance abuse.

“This MOU signifies a further collaboration with NZCR to support Novotech’s psychedelic therapy biotech clients. With their extensive experience and expertise in conducting clinical trials, coupled with a passionate team of psychiatrists deeply invested in this area, NZCR is an ideal research partner for exploring the therapeutic potential of psychedelics. Together with NZCR, we aim to unlock new insights, drive meaningful progress, and ultimately, make a positive impact on patients' lives, stated Dr. Barrett. 

NZCR CEO, Dr. Christian Schwabe said “NZCR has a close and long-standing relationship with Novotech, who we have successfully partnered with on previous psychedelic drug trials. We are excited about the opportunities this MOU brings as we continue to lead research in this therapeutic area”.

Novotech research has found that during the period from 2019 to 2023, nearly 75 psychedelic drug trials were initiated and remained ongoing. The trials are predominantly conducted in Europe and North America, accounting for 39% and 38% respectively. The Asia-Pacific region follows with 20%, while the Middle East, Africa, and South and Central America together hold 3% share.

The number of psychedelic drug trials had grown by more than fourfold from 2021 to 2023.

When analysing trials by phase the data shows Phase II dominates with 37 trials, followed by 11 trials each in Phase I and Phase III. Additionally, there were 4 trials in Phase I/II and 2 in Healthy Volunteers. The prominence of Phase II trials suggests a prime focus on assessing efficacy and dosing of psychedelic drugs in the period from 2019 to 2023.

NZCR was formed in 2020 through the merger of Auckland Clinical Studies (ACS) and Christchurch Clinical Studies Trust (CCST) and is New Zealand’s leading early phase clinical research provider. In 2023, NZCR acquired Optimal Clinical Trials, a late phase clinical trials operation, to form the NZCR Group. NZCR Group brings experience in over 850 trials involving over 20,000 participants.

With physician led, world class research sites and six units located in Auckland, Christchurch, Wellington, and Hamilton, the NZCR Group conducts complex multi-phase clinical research in healthy participant and patient populations.

Novotech 기업 소개 Novotech-CRO.com

1997년 설립된 노보텍은 글로벌 풀서비스 CRO이며 바이오텍과의 파트너십을 통해 임상의 모든 단계에서 혁신적이면서도 새로운 치료제 개발을 가속화하는데 주력하고 있습니다. 

CRO 업계를 주도적으로 이끌어온 공로를 인정받은 노보텍은 2006년부터 CRO Leadership Award 2023, Best Cell & Gene Therapy CRO 2023 상, Asia-Pacific Contract Research Organization Company of the Year Award 2023 등 다수의 권위 있는 상을 수상하였습니다. 

노보텍은 연구소, 임상 1상 시험 기관, 약물 개발 컨설팅 서비스, FDA 규제 전문성을 갖춘 임상 CRO 기업으로 1상에서 4상까지의 임상시험과 생물학적 동등성 연구를 포함해 5,000건 이상의 임상 프로젝트에 참여한 경험이 있습니다. 노보텍은 전 세계 지역에 걸쳐 34개 오피스와 3,000명 이상의 직원을 보유하고 있으며 신뢰할 수 있는 완전한 형태의 전략 파트너입니다. 

보다 더 자세한 정보를 원하거나 전문가 팀에게 문의할 사항이 있을 경우, 회사 홈페이지(www.Novotech-CRO.com)를 방문하시기 바랍니다. 

기타 관련 콘텐츠